Contract Manufacturing, Biopharmaceutical Production

Novavax and Fujifilm Diosynth Biotechnologies Begin Manufacturing of COVID-19 Vaccine Candidate

July 23, 2020

Fujifilm Diosynth Biotechnologies’ North Carolina site will be used to manufacture Novavax’ NVX‑CoV2373 vaccine candidate for a Phase III clinical trial.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Contractors Balance Increased Demand During COVID-19

July 01, 2020

BioPharm International

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Cobra Biologics to Manufacture AstraZeneca’s COVID-19 Vaccine Candidate

June 17, 2020

Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

June 01, 2020

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

Vibalogics Manufactures Clinical Trial Material for Janssen COVID-19 Vaccine Candidate

May 18, 2020

Vibalogics is contracted to manufacture Janssen's COVID-19 candidate vaccine at its GMP-accredited facility in Cuxhaven, Germany.

HCATS, apceth Biopharma Form Strategic Manufacturing Agreements with bluebird bio

May 13, 2020

Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.

Lonza, Moderna Form Global Collaboration to Manufacture Moderna’s COVID-19 Vaccine

May 01, 2020

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.

Biomanufacturing: Demand for Continuous Bioprocessing Increasing

May 01, 2020

BioPharm International

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.